Vis enkel innførsel

dc.contributor.authorVogt, Elinor Margrethe Chelsom
dc.contributor.authorBreivik, Lars Ertesvåg
dc.contributor.authorRøyrvik, Ellen Christine
dc.contributor.authorGrytaas, Marianne
dc.contributor.authorHusebye, Eystein Sverre
dc.contributor.authorØksnes, Marianne
dc.date.accessioned2022-04-12T09:40:03Z
dc.date.available2022-04-12T09:40:03Z
dc.date.created2021-07-07T14:36:28Z
dc.date.issued2021
dc.identifier.issn0021-972X
dc.identifier.urihttps://hdl.handle.net/11250/2991042
dc.description.abstractContext Primary ovarian insufficiency (POI) is defined by menopause before 40 years of age. POI prevalence is higher among women with autoimmune Addison’s disease (AAD) than in the general population, but their clinical characteristics are insufficiently studied. Objective To assess the prevalence of POI in a large cohort of women with AAD and describe clinical, immunological, and genetic characteristics. Methods An observational population-based cohort study of the Norwegian National Addison Registry. The Norwegian Prescription Database was used to assess prescription of menopausal hormone replacement therapy (HRT). A total of 461 women with AAD were studied. The primary outcome measure was prevalence of POI. Secondary outcomes were clinical characteristics, autoantibodies, and genome-wide single nucleotide polymorphism variation. Results The prevalence of POI was 10.2% (47/461) and one-third developed POI before 30 years of age. POI preceded or coincided with AAD diagnosis in more than half of the women. The prevalence of concomitant autoimmune diseases was 72%, and AAD women with POI had more autoantibodies than AAD women without (≥2 autoantibodies in 78% vs 25%). Autoantibodies against side-chain cleavage enzyme (SCC) had the highest accuracy with a negative predictive value for POI of 96%. HRT use was high compared to the age adjusted normal population (11.3 % vs 0.7%). Conclusion One in 10 women with AAD have POI. Autoantibodies against SCC are the most specific marker for autoimmune POI. We recommend testing women with AAD <40 years with menstrual disturbances or fertility concerns for autoantibodies against SCC.en_US
dc.language.isoengen_US
dc.publisherOxford University Pressen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/deed.no*
dc.titlePrimary ovarian insufficiency in women with Addison's diseaseen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2021 The Author(s)en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2
dc.identifier.doi10.1210/clinem/dgab140
dc.identifier.cristin1920754
dc.source.journalJournal of Clinical Endocrinology and Metabolism (JCEM)en_US
dc.source.pagenumbere2656-e2663en_US
dc.relation.projectNorges forskningsråd: 288022en_US
dc.relation.projectStiftelsen Kristian Gerhard Jebsen: KGJ senter for autoimmune sykdommeren_US
dc.relation.projectNorges forskningsråd: 262677en_US
dc.identifier.citationJournal of Clinical Endocrinology and Metabolism (JCEM). 2021, 106 (7), e2656-e2663.en_US
dc.source.volume106en_US
dc.source.issue7en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Attribution-NonCommercial-NoDerivatives 4.0 Internasjonal